San Diego-based Illumina, a developer of life science analysis tools, said Monday that the firm's products have been selected by Duke University Medical Center. According to Illumina, researchers at the school will use its Genome Analyzer to study resistance to HIV infection about individuals, who have been exposed but remain uninfected. Financial impact of the win was not disclosed. Illumina's Genome Analyzer product is used for gene sequencing applications. The Duke Unviversity study is being funded by a $3M grant from the Bill and Melinda Gates Foundation.